论文部分内容阅读
Objective: The aim of the study was to observe the effects of lobaplatin and oxaliplatin on biological behavior of colorectal carcinoma cell line. Methods: The human colorectal carcinoma cell line LoVo and HR-8348 were used in the present study, and different concentrations of lobaplatin and oxaliplatin served as inhibitors. The invasion and metastasis potential were evaluated with Transwell chamber, and cell inhibition ratio was measured with MTT assay. Results: Lobaplatin and oxaliplatin could significantly decrease the abilities of invasion and metastasis of LoVo and HR-8348 as compared with the control group (P < 0.01), but no difference between lobaplatin and oxaliplatin groups was observed (P > 0.05). No difference was found in the cell inhibition ratio between the lobaplatin and oxaliplatin groups (P > 0.05). Lobaplatin could inhibit colorectal carcinoma cells that oxaliplatin couldn’t do. Conclusion: Lobaplatin is a new antitumor platinum drug and can inhibit colorectal carcinoma cells. Moreover, lobaplatin could also inhibit colorectal carcinoma cells which are resistant to oxaliplatin.
Objective: The aim of the study was to observe the effects of lobaplatin and oxaliplatin on biological behavior of colorectal carcinoma cell line. Methods: The human colorectal carcinoma cell line LoVo and HR-8348 were used in the present study, and different concentrations of lobaplatin The invasion and metastasis potential were evaluated with the Transwell chamber, and the cell inhibition ratio was measured with the MTT assay. Results: Lobaplatin and oxaliplatin could significantly decrease the abilities of invasion and metastasis of LoVo and HR-8348 as compared with the control group (P <0.01), but no difference between lobaplatin and oxaliplatin groups was observed (P> 0.05). No difference was found in the cell inhibition ratio between the lobaplatin and oxaliplatin groups (P> 0.05). Lobaplatin could inhibit colorectal carcinoma cells that oxaliplatin could not do. Conclusion: Lobaplatin is a new antitumor platinum drug and can inhibit colorectal carci noma cells. Moreover, lobaplatin could also inhibit colorectal carcinoma cells which are resistant to oxaliplatin.